IAPP and Alzheimer disease: The former conditions could indeed offer an explanation why amylin deposits can be present in brain parenchyma of AD patients who do not suffer from full-blown T2DM (Jackson et al., 2013), whereas the latter condition could explain why augmentation of non-amyloidogenic amylin can exert beneficial effects on amyloid clearance from the CNS once marked amyloids had already been established (Adler et al., 2014; Zhu et al., 2015).